Gradalis, based in Dallas, TX, is a pioneering company at the forefront of cancer research and treatment. With a recent $9.9 million grant from the Cancer Prevention and Research Institute of Texas, Gradalis is developing Vigil, a personalized cancer immunotherapy with potential applications across various solid tumor types.
Through their unique process, Vigil is currently making strides in the fight against ovarian cancer, offering hope to patients seeking innovative treatment options. With a dedicated leadership team and board of directors, Gradalis is committed to revolutionizing cancer care and improving outcomes for individuals battling this disease.
Generated from the website